Phase I study of MLN8237 - Investigational Aurora A kinase inhibitor - In relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia

Investigational New Drugs

Volumn 32, Issue 3, 2014, Pages 489-499

  Kelly, Kevin R ^a   Shea, Thomas C ^b   Goy, André ^c   Berdeja, Jesus G ^d   Reeder, Craig B ^e   McDonagh, Kevin T ^f   Zhou, Xiaofei ^g   Danaee, Hadi ^g   Liu, Hua ^g   Ecsedy, Jeffrey A ^g   Niu, Huifeng ^g   Benaim, Ely ^g   Padmanabhan Iyer, Swaminathan ^h  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^d SARAH CANNON RESEARCH INSTITUTE   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

^g TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^h HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Aurora A kinase inhibitor; Cell cycle mechanisms of anticancer drug action; MLN8237; Novel antitumor agent; Phase I III Leukemia and lymphomas

Indexed keywords

ALISERTIB; AURORA A KINASE; HISTONE H3; ANTINEOPLASTIC AGENT; AURKA PROTEIN, HUMAN; AZEPINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW TOXICITY; BULLOUS DERMATITIS; CHROMOSOME 20; CHRONIC LYMPHATIC LEUKEMIA; CONFUSION; DIARRHEA; DRUG CAPSULE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERIC COATED TABLET; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; GENE DOSAGE; HUMAN; LARGE CELL LYMPHOMA; LEUKOCYTE COUNT; LEUKOPENIA; LOADING DRUG DOSE; LYMPHATIC LEUKEMIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPEN STUDY; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; POWDER; POWDER IN CAPSULE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; SOMNOLENCE; STOMATITIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; METABOLISM; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AURORA KINASE A; AZEPINES; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84904579971     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0050-9     Document Type: Article

References (34)

1. Barr AR, Gergely F (2007) Aurora-A: the maker and breaker of spindle poles. J Cell Sci 120:2987-2996 (Pubitemid 47517082)
2. Fu J, Bian M, Jiang Q, Zhang C (2007) Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 5:1-10
3. Marumoto T, Honda S, Hara T, Nitta M, Hirota T, Kohmura E et al (2003) Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 278:51786-51795 (Pubitemid 38020425)
4. Dutta-Simmons J, Zhang Y, Gorgun G, Gatt M, Mani M, Hideshima T et al (2009) Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. Blood 114:2699-2708
5. Evans R, Naber C, Steffler T, Checkland T, Keats J, Maxwell C et al (2008) Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells. Leuk Lymphoma 49:559-569 (Pubitemid 351298342)
6. Tomita M, Toyota M, Ishikawa C, Nakazato T, Okudaira T, Matsuda T et al (2009) Overexpression of Aurora A by loss of CHFR gene expression increases the growth and survival of HTLV-1-infected T cells through enhanced NF-kappaB activity. Int J Cancer 124:2607-2615
7. Ye D, Garcia-Manero G, Kantarjian HM, Xiao L, Vadhan-Raj S, Fernandez MH et al (2009) Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. J Hematop 2:2-8
8. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B et al (1998) A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17:3052-3065 (Pubitemid 28254378)
9. Wang X, Zhou YX, Qiao W, Tominaga Y, Ouchi M, Ouchi T et al (2006) Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 25:7148-7158 (Pubitemid 44764184)
10. Fukasawa K, Wiener F, Vande Woude GF, Mai S (1997) Genomic instability and apoptosis are frequent in p53 deficient young mice. Oncogene 15:1295-1302 (Pubitemid 27429745)
11. Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F et al (2004) Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 36:55-62 (Pubitemid 38056208)
12. Hata T, Furukawa T, Sunamura M, Egawa S, Motoi F, Ohmura Net al (2005) RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res 65:2899-2905 (Pubitemid 40490094)
13. Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M et al (2003) Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 114: 585-598 (Pubitemid 37159255)
14. Marumoto T, Hirota T, Morisaki T, Kunitoku N, Zhang D, Ichikawa Y et al (2002) Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian cells. Genes Cells 7:1173-1182 (Pubitemid 35256338)
15. Gorgun G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M et al (2010) A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 115: 5202-5213
16. Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM et al (2011) Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 17:7614-7624
17. Dees EC, Cohen RB, von Mehren M, Stinchcombe TE, Liu H, Venkatakrishnan K et al (2012) Phase I study of Aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res 18:4775-4784
18. Kelly KR, Nawrocki ST, Espitia CM, Zhang M, Yang JJ, Padmanabhan S et al (2012) Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Int J Cancer 131:2693-2703
19. Mahadevan D, Qi WQ, Cooke L, Lui XB, Persky DO, Rimsza LM et al (2009) Targeting Aurora kinase in aggressive B-cell Non-Hodgkin's lymphomas. Blood 114(22):Abstract 284
20. Friedberg J, Mahadevan D, Jung J, Cebula E, Persky D, Lossos I et al (2013) Phase II study of alisertib, a selective aurora A kinase inhibitor, in relapsed and refractory aggressive B- and Tcell non-Hodgkin lymphoma. J Clin Oncol. doi:10.1200/JCO. 2012.46.8793
21. Goldberg SL, Fenaux P, Craig MD, Gyan E, Lister J, Kassis J et al (2010) Phase 2 study of MLN8237, an investigational Aurora A Kinase (AAK) inhibitor in patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS). Blood (ASH Annual Meeting Abstracts) 116: abstract 3273
22. Mahadevan D, Stejskal A, Cooke LS, Manziello A, Morales C, Persky DO et al (2012) Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma. Clin Cancer Res 18: 2210-2219
23. Qi W, Cooke LS, Liu X, Rimsza L, Roe DJ, Manziolli A et al (2011) Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochem Pharmacol 81:881-890
24. Cervantes A, Elez E, Roda D, Ecsedy JA, Macarulla T, Venkatakrishnan K et al (2012) Phase I pharmacokinetic/ pharmacodynamic study of MLN8237 - an investigational, oral, selective, Aurora A Kinase inhibitor - in patients with advanced solid tumors. Clin Cancer Res 18:4764-4774
25. National Cancer Institute (2006) Common terminology criteria for adverse events version 3.0 (NCI-CTCAE). http://ctep.cancer.gov/protocoldevelopment/ electronic-applications/docs/ctcaev3.pdf. Accessed 11 September 2013
26. Cheson BD, Pfistner B, Juweid ME, Horning SJ, Coiffier B, Gascoyne RD et al (2006) Recommendations for revised response criteria for malignant lymphoma. J Clin Oncol (ASCO Annual Meeting) 24:18S (June 20 Supplement): abstract 7507
27. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586 (Pubitemid 350002966)
28. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473 (Pubitemid 44264086)
29. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456
30. Matulonis UA, Sharma S, Ghamande S, Gordon MS, Del Prete SA, Ray-Coquard I et al (2012) Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinumresistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol 127:63-69
31. Sharma S, Kurzrock R, Gouw L, Hong DS, Jones K, Zhou X et al (2011) Phase I dose-escalation study of the investigational Aurora A kinase (AAK) inhibitor MLN8237 as an enteric-coated tablet (ECT) formulation in patients with nonhematologic malignancies. J Clin Oncol 29(15-suppl):Abstract 3094
32. Hook KE, Garza SJ, Lira ME, Ching KA, Lee NV, Cao J et al (2012) An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther 11:710-719
33. Qi W, Spier C, Liu X, Agarwal A, Cooke LS, Persky DO et al (2013) Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leuk Res 37:434-439
34. Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, LeBlanc M et al (2013) Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 119:371-379